Disease · HP_0002524

Cataplexy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Cataplexy. Diseases, record HP_0002524. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002524

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Cataplexy
Open Targets ID: HP_0002524
Highest stage of its drugs: Approval, for 1 of its 8 drugs, from EMA Human Drugs

Source Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SODIUM OXYBATE	CHEMBL1200682	Small molecule	Approval	EMA Human Drugs	5	4	4	Drugs and targets
PITOLISANT	CHEMBL462605	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
MODAFINIL	CHEMBL1373	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
REBOXETINE	CHEMBL14370	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SUVN-G3031	CHEMBL4297328	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MAZINDOL	CHEMBL781	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
JNJ-17216498	CHEMBL3545030		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
OVEPOREXTON	CHEMBL6068065	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets6

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HRH3	Histamine H3 receptor	3	Histamine H3 receptor antagonist; Histamine H3 receptor inverse agonist	Phase 3	https://conductscience.org/library/genes/11255	Drugs and targets
SLC6A2	Monoamine transporter	2	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6530	Drugs and targets
SLC6A3	Monoamine transporter	2	Dopamine transporter inhibitor; Monoamine transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6531	Drugs and targets
GABBR1	GABA-B receptor	1	GABA-B receptor agonist	Approval	https://conductscience.org/library/genes/2550	Drugs and targets
GABBR2	GABA-B receptor	1	GABA-B receptor agonist	Approval	https://conductscience.org/library/genes/9568	Drugs and targets
SLC6A4	Monoamine transporter	1	Monoamine transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6532	Drugs and targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02720744	Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy	Phase 3	212	2022-03-22	Excessive Daytime Sleepiness, Cataplexy, Narcolepsy	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov
NCT03030599	A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy	Phase 3	201	2020-11-12	Narcolepsy With Cataplexy	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov
NCT04072380	A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy	Phase 2	190	2025-01-13	Narcolepsy	SUVN-G3031	Its record names the disease	ClinicalTrials.gov
NCT05687903	A Study of TAK-861 in Participants With Narcolepsy Type 1	Phase 2	112	2025-01-09	Narcolepsy Type 1	OVEPOREXTON	Its record names the disease	ClinicalTrials.gov
NCT02611687	Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period	Phase 3	110	2024-09-19	Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy	PITOLISANT	Its record names the disease	ClinicalTrials.gov
NCT02221869	A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy	Phase 3	106	2019-04-30	Narcolepsy With Cataplexy	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov
NCT00345800	Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes	Phase 1	25	2022-04-08	Narcolepsy With Cataplexy	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov
NCT07540364	A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE)	Phase 3	240		Narcolepsy	SUVN-G3031	Its record names the disease	ClinicalTrials.gov
NCT01638403	Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.	Phase 3	180		Treatment of Excessive Daytime Sleepiness in Narcolepsy	PITOLISANT	Its record names the disease	ClinicalTrials.gov
NCT01800045	Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)	Phase 3	103		Narcolepsy With Cataplexy, Excessive Daytime Sleepiness	PITOLISANT	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
JZP-258 vs Placebo: deaths from any cause	0 of 201	0 of 65	266	NCT03030599	Trial comparisons
JZP-258 vs Placebo: serious adverse events	5 of 201	2 of 65	266	NCT03030599	Trial comparisons
FT218 9g Group vs Placebo 9g Group: deaths from any cause	0 of 77	0 of 80	157	NCT02720744	Trial comparisons
FT218 9g Group vs Placebo 9g Group: serious adverse events	1 of 77	0 of 80	157	NCT02720744	Trial comparisons
Safety Population vs Randomized Placebo: deaths from any cause	0 of 104	0 of 32	136	NCT02221869	Trial comparisons
Safety Population vs Randomized Placebo: serious adverse events	2 of 104	0 of 32	136	NCT02221869	Trial comparisons
JZP-258 vs Placebo: Number of Participants With Worsening Patient Global Impression of Change (PGIc) for Narcolepsy Overall	3 of 69	29 of 65	134	NCT03030599	Trial comparisons
JZP-258 vs Placebo: Number of Participants With Worsening Clinical Global Impression of Change (CGIc) for Narcolepsy Overall	4 of 68	39 of 65	133	NCT03030599	Trial comparisons
Pitolisant vs Placebo: deaths from any cause	0 of 73	0 of 37	110	NCT02611687	Trial comparisons
Pitolisant vs Placebo: serious adverse events	0 of 73	0 of 37	110	NCT02611687	Trial comparisons

Papers from its trials22

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39504585	RESULT	1	PubMed
41359331	DERIVED	1	PubMed
40851446	DERIVED	1	PubMed
40367374	DERIVED	1	PubMed
40111739	DERIVED	1	PubMed
40111738	DERIVED	1	PubMed
39321628	DERIVED	1	PubMed
39153911	DERIVED	1	PubMed
37942930	DERIVED	1	PubMed
36947322	DERIVED	1	PubMed

1 to 10 of 22

See all 22 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0002524

GET https://conductscience.org/api/diseases/v1/HP_0002524/papers?page=2

API reference For AI assistants